The hosts discuss how Italy crossed the €1.2 billion equity fundraising threshold, driven by major players such as Bending Spoons and rapidly growing biotech companies. They explore AAVantgarde Bio’s €122M Series B round, highlighting its gene therapy innovation and strong international investor mix. The conversation then shifts to Atoptronics, a robotics spin-off developing electrostatic gripping technology with applications in space, logistics, and manufacturing. The hosts emphasize the rising quality of Italian deep-tech and how university spin-offs are becoming viable global contenders. Finally, they unpack TPG’s €1B offer for Nexi’s digital banking assets, analyzing valuation dynamics, interest-rate correlations, golden-power risks, and why the timing could be strategic for TPG. The episode concludes by noting how Italy’s tech landscape is maturing across biotech, robotics, and fintech.Niccolò's newsletter: ⁠⁠http://dealflowit.niccolosanarico.com/⁠⁠Watch on Youtube: ⁠https://www.youtube.com/@giacomomollo⁠Listen to all episodes on audio:Spotify: ⁠⁠https://spoti.fi/3fVynsQ⁠⁠Google Podcast: ⁠⁠https://bit.ly/3thf9RC⁠⁠Apple Podcast: ⁠⁠https://apple.co/3Elhykq⁠⁠Amazon Music: ⁠⁠https://shorturl.at/9Dtd9⁠⁠Get in touch:Instagram: ⁠⁠https://www.instagram.com/giacxxx⁠⁠Twitter: ⁠⁠https://twitter.com/giacomomollo⁠⁠Email: [email protected]#venturecapital #italy #startup

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related